oa SA Pharmaceutical Journal - Exsira® : a newer selective serotonin and noradrenaline reuptake inhibitor for the treatment of depression : new product focus - drug info

Volume 82, Issue 7
  • ISSN : 2221-5875
  • E-ISSN: 2220-1017



Exsira® 50 (100) mg extended-release tablets contain desvenlafaxine 50 mg and 100 mg, and are indicated for the treatment of major depressive disorder (MDD).

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error